Biocon acquires 70% stake in German firm
Biotechnology firm Biocon on Monday announced the acquisition of a 70 per cent stake in German pharmaceutical company, AxiCorp GmbH, for Euro 30 million (over Rs 173 crore), as part of its plan to become a major player in the insulin segment in Europe.
Friedrichsdorf (near Frankfurt) headquartered AxiCorp, a marketing and distribution company, had a turnover of Euro 75 million in 2007.
Biocon Chairman and Managing Director Kiran Mazumdar-Shaw told a press meet that the privately-held AxiCorp, founded in 2002, is a profitable firm. She, however, did not disclose the bottomline of the German company.
She said AxiCorp, which has launched more than 180 products, would add to the combined bottomline going forward.
"AxiCorp is a key strategic investment for Biocon as it heralds our European foray for biosimilars like Recombinant Human Insulin," Mazumdar-Shaw said, adding that the acquisition would help Biocon build strong marketing and distribution capabilities in Europe.
"Both companies share a common vision of affordable healthcare, which we can deliver through a combination of Biocon's low-cost manufacturing and AxiCorp's low-cost distribution," she said.
Mazumdar-Shaw said Biocon is focused on being a key player in the insulin segment and aiming to become the lowest cost insulin maker in the world market.
Biocon said the acquisition would enable marketing and distribution of a range of pharmaceuticals including generics, biosimilars, biologics and pharmaceutical products in Europe, particularly Germany.
Enter your email to get our daily newsletter in your inbox
- Facebook and Google are already partnered with Reliance and own stakes in Jio Platforms
- Gold set off to a brighter start at the beginning of the week as the price of the precious metal went up by ₹278 to ₹46,013 per 10 grams on Monday.
- According to the plan, new users will get a JioPhone device, unlimited voice calls and data (2GB high-speed data every month) for two years at ₹1,999.
- Britain's financial services industry has been largely cut off from the EU, its biggest customer, since a Brexit transition period ended on Dec. 31 as the sector is not covered by the UK-EU trade deal.